Biomarkers In Retinitis Pigmentosa (BIRP)
This trial is active, not recruiting.
|Treatment||anterior chamber (ac) tap|
|Sponsor||Johns Hopkins University|
|Start date||September 2013|
|End date||September 2018|
|Trial size||100 participants|
|Trial identifier||NCT01949623, BIRP|
In this study, markers of oxidative stress will be measured in the aqueous humour and plasma of RP patients compared to controls.
|Observational model||case control|
Aqueous levels of markers of oxidative stress in patients with RP and controls.
time frame: 2 years
Male or female participants from 18 years up to 100 years old.
Inclusion Criteria: - Signed informed consent and authorization of use and disclosure of protected health information - Age more than or equal to 18 years - For the study group, patients diagnosed with Retinitis Pigmentosa by the investigators - For the control group, patients undergoing vitreoretinal surgery for macular hole, epiretinal membrane, vitreomacular traction, retinal detachment, neovascular AMD and Diabetic Retinopathy will be eligible Exclusion Criteria: - Patients with active or suspected ocular or periocular infection
|Official title||Biomarkers In Retinitis Pigmentosa (BIRP)|
|Principal investigator||Peter Campochiaro, MD|
|Description||People with Retinitis Pigmentosa have loss of night vision followed by loss of central vision due to damage and death of photoreceptors. One of the mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific biomarkers which can be measured. In this study, these biomarkers will be assessed in people with Retinitis Pigmentosa and compared to controls.|
Call for more information